Antonella Sistigu
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.
Journal: Clinical lung cancer
Published: January 11, 2026
E. Coli cytotoxic necrotizing factor-1 promotes colorectal carcinogenesis by causing oxidative stress, DNA damage and intestinal permeability alteration.
Journal: Journal of experimental & clinical cancer research : CR
Published: November 23, 2024
Author Correction: Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.
Journal: Nature immunology
Published: September 17, 2024
Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle.
Journal: Journal of visualized experiments : JoVE
Published: June 24, 2024
In Vitro Evaluation of Cancer Cell Immunogenicity and Antigen-Specific T-Cell Cytotoxicity by Flow Cytometry.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: December 09, 2023
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer.
Journal: Journal of translational medicine
Published: July 04, 2023
3D cancer models: One step closer to in vitro human studies.
Journal: Frontiers in immunology
Published: February 27, 2023
Apoptotic cell death in disease-Current understanding of the NCCD 2023.
Journal: Cell death and differentiation
Published: January 30, 2023
Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?
Journal: Biology
Published: August 04, 2021
The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation.
Journal: Biology
Published: August 01, 2021
Last Updated: 09/26/2026